Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

Fig. 4

Odds ratios for achieving efficacy endpoints at week 24 by baseline biomarker tertile. Odds ratios (sarilumab vs. adalimumab) for achieving ACR20, ACR50 and DAS28-CRP < 3.2 responses at week 24 by baseline biomarker tertile. *Nominal biomarker-by-treatment interaction vs. low tertile. Low, medium and high subgroups are based on biomarker tertile values in overall treatment groups (see Table S3 for tertile ranges). ACR20/50, American College of Rheumatology 20/50% improvement criteria; CI, confidence interval; DAS28-CRP, Disease Activity Score (28 joints) using C-reactive protein; MMP-3, matrix metalloproteinase-3; NS, not significant at 5%; SAA, serum amyloid A

Back to article page